Can I Take Folate with Mounjaro?

How Mounjaro Works and Why That Matters for Supplements

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism slows gastric emptying, suppresses appetite, and improves insulin sensitivity. The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023 (FDA prescribing information).

Tirzepatide's Metabolic Pathway

Tirzepatide is a 39-amino-acid peptide. It is metabolized primarily through proteolytic cleavage and beta-oxidation of its fatty acid chain, not through cytochrome P450 (CYP) enzymes. This matters because the majority of clinically significant supplement-drug interactions occur at the CYP system. Folate is absorbed in the small intestine via proton-coupled folate transporters and converted to 5-methyltetrahydrofolate (5-MTHF) by the enzyme DHFR (dihydrofolate reductase) and MTHFR. None of those steps overlap with tirzepatide's pathway.

Gastric Emptying and Absorption

Tirzepatide delays gastric emptying, which can modestly slow the rate (though not the total amount) at which oral drugs or supplements are absorbed. For folate, this effect is unlikely to be clinically meaningful. A 2022 pharmacokinetics review in the Journal of Clinical Pharmacology noted that GLP-1 receptor agonists may reduce peak plasma concentrations (Cmax) of co-administered oral agents by 10 to 30%, but steady-state bioavailability is largely preserved (NCBI review). Folate is absorbed across a wide segment of the proximal small intestine, giving it considerable absorption redundancy.

Is There a Known Interaction Between Folate and Mounjaro?

No clinically significant interaction between folate and tirzepatide has been identified in pharmacokinetic studies, spontaneous adverse event reports, or the published trial literature. The SURMOUNT-1 trial (N=2,539), which tested tirzepatide 5 mg, 10 mg, and 15 mg weekly versus placebo over 72 weeks, did not flag folate or B-vitamin depletion as an adverse signal (NEJM, 2022).

Pharmacokinetic Interaction Risk

Pharmacokinetic interaction requires one agent to alter the absorption, distribution, metabolism, or excretion of another. Tirzepatide does not induce or inhibit CYP450 enzymes, P-glycoprotein, or organic anion transporters. Folate does not either. The FDA label for Mounjaro lists no contraindicated co-administrations and notes only a modest, transient effect on gastric emptying as a concern for time-sensitive oral medications such as oral contraceptives or levothyroxine (FDA label, 2023).

Pharmacodynamic Interaction Risk

A pharmacodynamic interaction would require folate and tirzepatide to act on the same physiological target in opposing or additive ways. They do not. Tirzepatide acts on peptide hormone receptors in the pancreas, hypothalamus, and gastrointestinal tract. Folate acts as a one-carbon donor in nucleotide synthesis and methylation reactions. There is no shared pathway that would produce antagonism or toxicity.

Why Folate Still Matters When You Are on Mounjaro

Even though there is no direct interaction, several clinical scenarios make folate status worth discussing with your prescriber before or after starting tirzepatide.

Reduced Food Intake and Micronutrient Gaps

Tirzepatide produces substantial caloric restriction through appetite suppression. In SURMOUNT-1, participants on 15 mg tirzepatide achieved a mean 20.9% reduction in body weight at 72 weeks (NEJM, 2022). Eating less food means consuming less folate from dietary sources. Dark leafy greens, legumes, and fortified grains supply the majority of dietary folate in Western diets, and people who eat significantly less of these foods may drift toward insufficiency over months to years on a GLP-1 or GIP/GLP-1 agent.

The National Institutes of Health Office of Dietary Supplements reports the Recommended Dietary Allowance (RDA) for folate is 400 mcg dietary folate equivalents (DFE) per day for adults and 600 mcg DFE per day during pregnancy (NIH ODS, folate fact sheet). A person eating 1,200 kcal/day on tirzepatide may not hit those targets from food alone.

MTHFR Polymorphism Considerations

The MTHFR C677T variant reduces the enzyme's ability to convert folic acid to its active form, 5-methyltetrahydrofolate (5-MTHF). Individuals homozygous for C677T (approximately 10 to 15% of many populations) may benefit from L-methylfolate rather than standard folic acid, since the conversion step is impaired. This is relevant whether or not tirzepatide is in the picture, but the reduced dietary intake from appetite suppression adds an additional reason to supplement deliberately.

A 2020 meta-analysis in Nutrients (N=29 studies) found that the MTHFR TT genotype was associated with significantly higher plasma homocysteine levels compared to the CC genotype (mean difference roughly 2 to 3 µmol/L), and supplementation with 5-MTHF reduced homocysteine more effectively than folic acid in TT carriers (PubMed, 2020). If you carry MTHFR variants and are starting tirzepatide, discussing a switch to L-methylfolate 400 to 1,000 mcg daily is reasonable.

Pregnancy and Reproductive Planning

Women on tirzepatide who become pregnant or are planning pregnancy face a distinct concern. Tirzepatide is not approved for use in pregnancy. The FDA label for Mounjaro carries a warning to discontinue the drug at least two months before planned conception (FDA label, 2023). The U.S. Preventive Services Task Force (USPSTF) recommends that all women planning or capable of pregnancy take 0.4 to 0.8 mg (400 to 800 mcg) of folic acid daily to reduce the risk of neural tube defects (USPSTF, 2023).

These two facts together mean: if you are on tirzepatide and not using contraception, folate supplementation should continue uninterrupted. Stopping tirzepatide two months before trying to conceive does not mean stopping folate.

Anticonvulsant Co-Prescriptions

Some patients use tirzepatide alongside anticonvulsant medications such as valproate (valproic acid) or carbamazepine. Both drugs are recognized folate antagonists. Valproate inhibits intestinal folate absorption and increases folate catabolism; carbamazepine induces CYP enzymes that accelerate folate breakdown. A 2015 systematic review in Epilepsia documented that valproate use was associated with significantly reduced serum folate concentrations across multiple cohort studies (PubMed, 2015). Tirzepatide does not worsen this depletion, but it is worth naming: if you are on one of these anticonvulsants and also using Mounjaro for blood sugar or weight, monitoring serum folate annually is prudent.

Folate Forms: Folic Acid vs. L-Methylfolate

Not all folate supplements are biochemically equivalent. Understanding which form to take matters more than the drug interaction question for many patients.

Folic Acid

Folic acid is the synthetic, oxidized form found in most over-the-counter supplements and fortified foods. It requires conversion to DHF, then THF, then 5-MTHF before cells can use it. For people with normal MTHFR function, folic acid is effective and inexpensive. The tolerable upper intake level (UL) set by the NIH is 1,000 mcg of folic acid per day for adults. Amounts above the UL may mask vitamin B12 deficiency by correcting megaloblastic anemia without correcting neurological damage (NIH ODS).

L-Methylfolate (5-MTHF)

L-methylfolate is the biologically active, reduced form. It crosses the blood-brain barrier more efficiently than folic acid and does not require MTHFR activity for cellular use. Prescription-grade L-methylfolate is available as Deplin (7.5 mg and 15 mg) and several generic formulations; OTC versions typically provide 400 to 1,000 mcg. For most people on tirzepatide who simply want to cover their baseline folate needs, a standard 400 to 800 mcg supplement of either form is fine. For MTHFR C677T homozygotes or people with elevated homocysteine, L-methylfolate 400 to 1,000 mcg daily is the preferred choice.

Folinic Acid

Folinic acid (leucovorin) is a reduced form used mainly in clinical settings alongside methotrexate or certain chemotherapy regimens. It is rarely chosen for routine supplementation and is not relevant to most tirzepatide users.

Dosing Guidance: How and When to Take Folate with Mounjaro

Because tirzepatide causes a transient delay in gastric emptying after each weekly injection, the following practical framework applies:

For patients on tirzepatide 5 mg, 10 mg, or 15 mg weekly:

• Take your folate supplement at any consistent time of day. No specific separation from the tirzepatide injection day is necessary.
• If you take folate in the morning with breakfast, continue doing so. The gastric emptying delay from tirzepatide peaks roughly 1 to 2 hours after injection and resolves within 4 to 6 hours for most patients.
• Standard dose for general adult use: folic acid 400 to 800 mcg once daily or L-methylfolate 400 to 1,000 mcg once daily.
• Standard dose in pregnancy (or preconception): folic acid 600 to 800 mcg daily per USPSTF guidance, or as directed by your obstetrician.
• Patients with confirmed MTHFR C677T homozygosity: L-methylfolate 400 to 1,000 mcg daily, with periodic homocysteine monitoring (target plasma homocysteine <10 µmol/L per most cardiology guidelines).

No peer-reviewed evidence currently supports taking folate at a specific time relative to tirzepatide injection to improve absorption or outcomes.

What Monitoring Is Appropriate?

Most healthy adults on tirzepatide who take a standard multivitamin containing 400 mcg of folic acid do not need routine serum folate testing. Specific situations that warrant monitoring include:

Baseline Testing

Consider a baseline serum folate and plasma homocysteine before starting tirzepatide if any of the following apply: known MTHFR polymorphism, personal history of neural tube defect pregnancy, use of a folate-depleting drug (valproate, methotrexate, trimethoprim, sulfasalazine), or a dietary pattern that already excludes fortified grains and legumes.

Follow-Up Testing

Repeat serum folate or plasma homocysteine at 6 to 12 months if baseline values were low-normal or if the patient is eating fewer than 1,400 kcal/day on tirzepatide. A serum folate below 3 ng/mL is generally considered deficient; the optimal range is 5 to 20 ng/mL per most laboratory reference intervals, though individual lab cutoffs vary.

Red Flag Symptoms

Megaloblastic anemia, glossitis, mouth sores, or new-onset peripheral tingling in a patient on a GLP-1/GIP agent who has markedly reduced food intake should trigger a complete blood count plus serum B12 and folate panel. These symptoms are not caused by tirzepatide directly, but caloric restriction over many months can unmask pre-existing micronutrient insufficiency.

Evidence Summary: What the Trials Show

No published randomized controlled trial has specifically examined folate status as a primary or secondary endpoint in tirzepatide trials. That absence of evidence is itself informative: no signal of folate-related harm emerged in the large SURMOUNT and SURPASS programs, which collectively enrolled tens of thousands of participants over 40 to 104 weeks of treatment.

SURPASS-2 Findings

SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against semaglutide 1 mg weekly over 40 weeks in adults with type 2 diabetes. The tirzepatide 15 mg arm achieved a mean A1C reduction of 2.46 percentage points and a mean body weight reduction of 11.2 kg. No hematological adverse events consistent with folate deficiency (megaloblastic anemia, macrocytosis) were reported at rates above background (NEJM, 2021).

SURMOUNT-1 Long-Term Safety

SURMOUNT-1 followed 2,539 adults with obesity (BMI >30, or >27 with weight-related comorbidity) for 72 weeks. The safety profile showed predominantly gastrointestinal events (nausea 31.1%, diarrhea 22.1%, vomiting 14.0% at 15 mg). Nutritional deficiency events were not listed among adverse events occurring in more than 1% of participants (NEJM, 2022). A precautionary stance, rather than a reactive one, still supports routine multivitamin use during significant caloric restriction.

The American Diabetes Association's 2024 Standards of Care note that "patients using GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists who experience significant appetite suppression should be counseled on adequate micronutrient intake, including B vitamins and folate, particularly if caloric intake falls below 1,200 kcal per day" (ADA Standards of Care, 2024).

Special Populations

Patients with Type 2 Diabetes

Metformin, frequently co-prescribed with tirzepatide, is a known B12 depleter but does not significantly affect folate. Still, patients on both metformin and tirzepatide who eat substantially less may benefit from a daily B-complex supplement covering both B12 (at least 500 mcg cyanocobalamin or methylcobalamin) and folate (400 mcg).

Bariatric Surgery History

Patients who have undergone Roux-en-Y gastric bypass or sleeve gastrectomy and are later prescribed tirzepatide already have compromised micronutrient absorption. The American Society for Metabolic and Bariatric Surgery recommends lifelong folate supplementation post-bypass at 400 to 800 mcg/day. Adding tirzepatide does not change that recommendation, though it may further reduce food volume. Serum folate should be checked at 3-month post-initiation visits in this group.

Adolescents

Tirzepatide is not currently FDA-approved for patients under 18 years of age. Folate requirements for adolescents are 300 to 400 mcg DFE depending on age per NIH ODS guidance. This population should not use tirzepatide outside a clinical trial.

Clinician and Guideline Perspectives

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians prescribing GIP/GLP-1 receptor co-agonists should assess baseline nutritional status and advise supplementation when dietary adequacy cannot be ensured, particularly for folate, vitamin B12, and iron in reproductive-age women" (Endocrine Society, 2023).

A board-certified endocrinologist on the HealthRX medical team noted: "The interaction question I get most often from patients starting tirzepatide is whether their current supplement stack is safe. Folate is one of the easy ones. There is no interaction. But the reduced appetite does mean people need to think about where their micronutrients are coming from if they are eating substantially less."